Zzbeacon,Zayna [MR ]
|
|
|
- Rosa Houston
- 5 years ago
- Views:
Transcription
1 AALL1131 MAINTENANCE, ARM B, HR-ALL Properties Laboratory and Take-Home Medications 9/26/2012, Planned Laboratory and Take-Home Medications Planned for 9/26/2012 Release Take-Home Medications prednisone (DELTASONE) tablet 23 mg 20 mg/m m2 (Treatment plan actual BSA) = 23 mg, Oral, 2 Times Daily, Starting S As Scheduled, For 8 doses mercaptopurine (PURINETHOL) 50 mg tablet Take 2 tablets by mouth daily. Give at least 1 hour after evening meal. To be taken without milk or citrus products. Normal, R-0 Release Release Release 75 mg/m2 (87 mg = 1.74 tablet) cannot be prescribed using the selected product. The nearest available dose is 100 mg (86.2 mg/m2). mercaptopurine (PURINETHOL) 50 mg tablet Take by mouth daily. Normal, R-0 Release methotrexate 5 MG tablet Take 5 tablets by mouth once a week. Take by mouth weekly on clinic day. Omit on week of spinal tap. Normal, R-1 Release Cycle 1 9/27/2012 through 12/19/2012 (84 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Comprehensive metabolic panel Bilirubin, direct (GH L Q YH) CSF cell count with differential (L YH) 9/27/2012 3:25:35 PM Page 1 of 8
2 open., Starting 4 HOURS PRN, Nausea or vomiting, Starting midazolam (VERSED) injection 1.79 mg 0.05 mg/kg 35.8 kg (Treatment plan actual weight) = 1.79 mg, Intravenous, PRN, for sedation for procedure., Starting, For 3 doses fentanyl PF (SUBLIMAZE) injection 36 mcg 1 mcg/kg 35.8 kg (Treatment plan actual weight) = 36 mcg, IV Push, PRN, for sedation for procedure., Starting, For 3 doses naloxone (NARCAN) injection 0.36 mg 10 mcg/kg 35.8 kg (Treatment plan actual weight) = 0.36 mg, IV Push, PRN, Opioid Reversal, Starting, For 10 doses May repeat every 2-3 minutes. flumazenil (ROMAZICON) injection mg 0.01 mg/kg 35.8 kg (Treatment plan actual weight) = mg, Intravenous, PRN, for benzodiazepine reversal., Starting, For 5 doses Ordered dose of 0.01 mg/kg PRN exceeds the recommended single dose limit of 0.2 mg. lidocaine (LMX) 4 % cream Topical, PRN, for procedure sites., Starting methotrexate, hydrocortisone sodium succinate (Solu-CORTEF), cytarabine (CYTOSAR) in sodium chloride 0.9 % PF INTRATHECAL chemo injection Intrathecal, ONCE, Starting at treatment start time, For 1 dose Prepared in preservative-free 0.9% sodium chloride. Administration is by MD or other licensed oncology provider. Minutes, ONCE, Starting, For 1 dose draw/administration., Starting Day 29, Cycle 1 Planned for 10/25/2012 9/27/2012 3:25:35 PM Page 2 of 8
3 CSF cell count with differential (L YH) open., Starting 4 HOURS PRN, Nausea or vomiting, Starting midazolam (VERSED) injection 1.79 mg 0.05 mg/kg 35.8 kg (Treatment plan actual weight) = 1.79 mg, Intravenous, PRN, for sedation for procedure., Starting, For 3 doses fentanyl PF (SUBLIMAZE) injection 36 mcg 1 mcg/kg 35.8 kg (Treatment plan actual weight) = 36 mcg, IV Push, PRN, for sedation for procedure., Starting, For 3 doses naloxone (NARCAN) injection 0.36 mg 10 mcg/kg 35.8 kg (Treatment plan actual weight) = 0.36 mg, IV Push, PRN, Opioid Reversal, Starting, For 10 doses May repeat every 2-3 minutes. flumazenil (ROMAZICON) injection mg 0.01 mg/kg 35.8 kg (Treatment plan actual weight) = mg, Intravenous, PRN, for benzodiazepine reversal., Starting, For 5 doses Ordered dose of 0.01 mg/kg PRN exceeds the recommended single dose limit of 0.2 mg. lidocaine (LMX) 4 % cream Topical, PRN, for procedure sites., Starting methotrexate in sodium chloride 0.9 % 5 ml PF INTRATHECAL chemo injection Intrathecal ONCE, Starting, For 1 dose Prepared in preservative-free 0.9% sodium chloride. Administration is by MD or other licensed oncology provider. Minutes, ONCE, Starting, For 1 dose 9/27/2012 3:25:35 PM Page 3 of 8
4 draw/administration., Starting Day 57, Cycle 1 Planned for 11/22/2012 open., Starting 4 HOURS PRN, Nausea or vomiting, Starting Minutes, ONCE, Starting, For 1 dose draw/administration., Starting 9/27/2012 3:25:35 PM Page 4 of 8
5 Cycle 2 12/20/2012 through 3/13/2013 (84 days), Planned Cycle 3 3/14/2013 through 6/5/2013 (84 days), Planned Cycle 4 6/6/2013 through 8/28/2013 (84 days), Planned Cycle 5 8/29/2013 through 11/20/2013 (84 days), Planned Day 1, Cycle 5 Planned for 8/29/2013 Comprehensive metabolic panel Bilirubin, direct (GH L Q YH) CSF cell count with differential (L YH) open., Starting 4 HOURS PRN, Nausea or vomiting, Starting midazolam (VERSED) injection 1.79 mg 0.05 mg/kg 35.8 kg (Treatment plan actual weight) = 1.79 mg, Intravenous, PRN, for sedation for procedure., Starting, For 3 doses fentanyl PF (SUBLIMAZE) injection 36 mcg 1 mcg/kg 35.8 kg (Treatment plan actual weight) = 36 mcg, IV Push, PRN, for sedation for procedure., Starting, For 3 doses naloxone (NARCAN) injection 0.36 mg 10 mcg/kg 35.8 kg (Treatment plan actual weight) = 0.36 mg, IV Push, PRN, Opioid Reversal, Starting, For 10 doses May repeat every 2-3 minutes. 9/27/2012 3:25:35 PM Page 5 of 8
6 flumazenil (ROMAZICON) injection mg 0.01 mg/kg 35.8 kg (Treatment plan actual weight) = mg, Intravenous, PRN, for benzodiazepine reversal., Starting, For 5 doses Ordered dose of 0.01 mg/kg PRN exceeds the recommended single dose limit of 0.2 mg. lidocaine (LMX) 4 % cream Topical, PRN, for procedure sites., Starting methotrexate, hydrocortisone sodium succinate (Solu-CORTEF), cytarabine (CYTOSAR) in sodium chloride 0.9 % PF INTRATHECAL chemo injection Intrathecal, ONCE, Starting at treatment start time, For 1 dose Prepared in preservative-free 0.9% sodium chloride. Administration is by MD or other licensed oncology provider. Minutes, ONCE, Starting, For 1 dose draw/administration., Starting Day 29, Cycle 5 Planned for 9/26/2013 CSF cell count with differential (L YH) 9/27/2012 3:25:35 PM Page 6 of 8
7 open., Starting 4 HOURS PRN, Nausea or vomiting, Starting Minutes, ONCE, Starting, For 1 dose draw/administration., Starting Day 57, Cycle 5 Planned for 10/24/2013 open., Starting 4 HOURS PRN, Nausea or vomiting, Starting Minutes, ONCE, Starting, For 1 dose 9/27/2012 3:25:35 PM Page 7 of 8
8 draw/administration., Starting Cycle 6 11/21/2013 through 2/12/2014 (84 days), Planned Cycle 7 2/13/2014 through 5/7/2014 (84 days), Planned Cycle 8 5/8/2014 through 7/30/2014 (84 days), Planned Cycle 9 7/31/2014 through 10/22/2014 (84 days), Planned Cycle 10 10/23/2014 through 1/14/2015 (84 days), Planned Cycle 11 1/15/2015 through 4/8/2015 (84 days), Planned Cycle 12 4/9/2015 through 7/1/2015 (84 days), Planned 9/27/2012 3:25:35 PM Page 8 of 8
Zzbeacon,Zayna [MR ]
![Zzbeacon,Zayna [MR ]](/thumbs/86/93872827.jpg "Zzbeacon,Zayna [MR ]")
AALL1131 INTERIM MAINTENANCE, HR-ALL, ARM B, HD MTX Properties Cycle 1 9/27/2012 through 11/28/2012 (63 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Release CBC and differential Release Release
Zzbeacon,Zayna [MR ]
![Zzbeacon,Zayna [MR ]](/thumbs/89/98203205.jpg "Zzbeacon,Zayna [MR ]")
AALL1131-DS INDUCTION HR-ALL, DAYS 1-14 Properties Cycle 1 9/27/2012 through 10/10/2012 (14 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Release Labs CBC and differential Release Release Comprehensive
PHYSICIAN ORDERS Diagnosis
PICU PROCEDURE PLAN PHYSICIAN S Diagnosis Weight Allergies DETAILS Admit/Discharge/Transfer Patient Status Pt Status: Inpatient (LOS > 2 midnights) Pt Status: Observation (LOS < 2 midnights) Patient Care
(30689) PROT Pain PCA Adult Patient Controlled Analgesia
Diagnosis Allergies Nursing Assess and Document PCA: 1. Assess and document pain rating, sedation level and respiratory rate every 2 hours; assess and document pain rating, sedation level and respiratory
PEDIATRIC ANALGESIA AND SEDATION DRUG MANUAL
PEDIATRIC ANALGESIA AND SEDATION DRUG MANUAL HARBOR-UCLA MEDICAL CENTER PEDIATRIC ANALGESIA AND SEDATION DRUG MANUAL SECTION Preface Disclaimer Nonpharmacologic Methods Table of Contents PAGE i ii iii
Appendix A: Pharmacologic approaches to pain management during MVA
Pain medication Though the medications shown below are commonly used for pain management during uterine evacuation, many other options exist. This table does not cover general anesthetic agents. Both anxiolytics
DEEP SEDATION TEST QUESTIONS
Mailing Address: Phone: Fax: The Study Guide is provided for those physicians eligible to apply for Deep Sedation privileges. The Study Guide is approximately 41 pages, so you may consider printing only
Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline
Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline 1. Pharmacist to order Narcotic Withdrawal Scores QH X 4 hours, then per table below: Narcotic Withdrawal Score
RITUXIMAB RHEUMATOLOGY VASCULITIS
. PHYSICIAN (Patient Sticker) ORDER SET : CDH 208-237 Approved - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name:
POST TEST: PROCEDURAL SEDATION
POST TEST: PROCEDURAL SEDATION Name: Date: Instructions: Complete the Post-Test (an 85% is required to pass). If there are areas that you are unsure of, please review the relevant portions of the learning
Chapter 19. Media Directory. Topical (Surface) Anesthesia. Spinal Anesthesia. Nerve-Block Anesthesia. Infiltration (Field-Block) Anesthesia
Chapter 19 Drugs for Local and General Anesthesia Slide 18 Media Directory Lidocaine Animation Upper Saddle River, New Jersey 07458 All rights reserved. Topical (Surface) Anesthesia Creams, sprays, suppositories
Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
Cardiac Catheter Labs Intravenous Drug Therapy Guide
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab
Methylprednisolone iv to po dose
Methylprednisolone iv to po dose The Borg System i Methylprednisolone iv to po dose PRESTON T. PHILLIPS A R C H I T E C T ford residence southampton, ny Methylprednisolone iv to po dose Chemotherapy. Cytarabine
ALL Phase 2 Induction (25-60 years)
ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
ALL MAINTENANCE (25-60 years)
ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may
PHYSICIAN PROCEDURAL SEDATION AND ANALGESIA QUIZ
PHYSICIAN PROCEDURAL SEDATION AND ANALGESIA QUIZ 1. Which of the following statements are TRUE? (Select ALL that apply) o Sedative/analgesic drugs should be given in small, incremental doses that are titrated
Sample. Affix patient label within this box.
Instructions for completing orders: Determine PRAM Clinical Score as per the Alberta Acute Childhood Asthma Pathway for Emergent/Urgent Care and select orders based on PRAM Score. Custom orders can be
Neurosurgery Pre-Op [1710] Patient Name MRN. General. Nursing. Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT [ ] Other
![Neurosurgery Pre-Op [1710] Patient Name MRN. General. Nursing. Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT [ ] Other](/thumbs/96/128298591.jpg "Neurosurgery Pre-Op [1710] Patient Name MRN. General. Nursing. Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT [ ] Other")
Neurosurgery Pre-Op [1710] Patient Name MRN General Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT Inpatient Only Procedure (Single Response) ( ) Admit to Inpatient Diagnosis:
Care of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
(31189) Hypothermia Initiation Phase One
Hypothermia Initiation Phase One Diagnosis Allergies For hypothermia tracking purposes only. Please do not uncheck.- Required Cardiac Emergency Tracking For hypothermia tracking purposes only. Consults
Care of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
Gazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
Sedation in Children
CHILDREN S SERVICES Sedation in Children See text for full explanation and drug doses Patient for Sedation Appropriate staffing Resuscitation equipment available Monitoring equipment Patient suitability
Attestation for Completion of Procedural Sedation Course for Level I Moderate Procedural Sedation Privileges
Attestation for Completion of Procedural Sedation Course for Level I Moderate Procedural Sedation Privileges I certify that I have completed the following: I have read the PHSW Procedural Sedation Policy
Drug Max dose approved for IVP Dilution Rate Monitoring Parameters. Dilution not necessary (Available in prefilled syringe)
Drug Max dose approved for IVP Dilution Rate Monitoring Parameters Acetazolamide 500 mg Reconstitute with at least 5ml sterile water (max concentration should not exceed 100mg/ml) 100-500 mg/min Hypotension
Pediatric Sedation Pocket Reference
Pediatric Sedation Pocket Reference No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopy, recording,
ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)
ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) CLASSIFICATION OF TREATMENT GROUPS: 1. Isolated Skin lesions, < 5 skin lesions. Treatment course: ( No treatment, wait and see approach)
EXAMPLE TREATMENT AND SCHEMAS. Study Treatment: GENERAL GUIDELINES
EXAMPLE TREATMENT AND SCHEMAS Study Treatment: GENERAL GUIDELINES Do not abbreviate agent names or treatment schedules. Abbreviations can be misinterpreted. Use complete approved generic agent names. Brand
INPATIENT INTERVENTIONAL RADIOLOGY PLAN - Phase: Pre-Procedure Orders
- Phase: Pre-Procedure Orders DETAILS Patient Care Obtain Consent If one is not present on chart today. Vital Signs Per Policy Insert Peripheral Line T;N, Start IV on right side If left radial access is
Procedural Sedation in the Rural ER
Procedural Sedation in the Rural ER Hal Irvine MD FCFP Rural FP Anesthetist Sundre, Alberta June 17, 2011 Disclosure I do not have any affiliations (financial or otherwise) with a commercial organization
PAIN PODCAST SHOW NOTES:
PAIN PODCAST SHOW NOTES: Dallas Holladay, DO Ultrasound Fellow Cook County Hospital Rush University Medical Center Jonathan D. Alterie, DO PGY-2, Emergency Medicine Midwestern University An overview of
Analgesic-Sedatives Drug Dose Onset
Table 4. Commonly used medications in procedural sedation and analgesia Analgesic-Sedatives Fentanyl Morphine IV: 1-2 mcg/kg Titrate 1 mcg/kg q3-5 minutes prn IN: 2 mcg/kg Nebulized: 3 mcg/kg IV: 0.05-0.15
ADMINISTRATIVE POLICY AND PROCEDURE MANUAL. Subject: Moderate Sedation/Analgesia- Procedural ( Conscious Sedation ) Policy
BRYN MAWR HOSPITAL LANKENAU HOSPITAL PAOLI HOSPITAL Working Together to Serve the Community ADMINISTRATE POLICY AND PROCEDURE MANUAL Subject: Moderate Sedation/Analgesia- Procedural ( Conscious Sedation
PHYSICIAN ORDER SET : Patient: DOB: Gender: Patient Phone #: Height: Weight:
. (Patient Sticker) CDH 208-203 Approved 2/18 - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name: Ordering Provider:
Motion Approved by Council February 20, Revoke subsections 1 (2) and (3) and substitute the following:
Item 5.3 Motion Approved by Council February 20, 2015 Recommending that Council approve in principle the following amendments to O. Reg. 203/94, namely: 1. Revoke subsections 1 (2) and (3) and substitute
OSF NORTHERN REGION EMERGENCY MEDICAL SERVICES STANDING MEDICAL ORDERS ILS, ALS. SMO: Adult Pain Management
OSF NORTHERN REGION EMERGENCY MEDICAL SERVICES STANDING MEDICAL ORDERS ILS, ALS SMO: Adult Pain Management Overview: Objective: Provide a reasonable relief of severe pain to make packaging and transport
Moderate and Deep Sedation Pathway
A Quick Reference to the Advocate System Sedation Policy *This information is meant as a guideline only and not a substitute for physician order or clinical judgment Introduction: This Pediatric Emergency
FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1)
FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1) AML19 Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome ***Refer to trial protocol
Original Date of issue: 01/11/2005 Last Reviewed: 01/05/2011 Version:4 Page 1 of 7
Original Date of issue: 01/11/2005 Last eviewed: 01/05/2011 Version:4 Page 1 of 7 15: Anaesthesia 15.1 General anaesthesia 15.1.1 Intravenous anaesthesia Etomidate Injection (20mg/10ml) Ketamine Injection
INFLIXIMAB RHEUMATOLOGY LOAD DOSE (SCHEDULE WEEKS 0, 2, 6)
. INFLIXIMAB RHEUMATOLOGY LOAD DOSE (SCHEDULE CDH 208-211 Approved 2/18 - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility
PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase:.
- Phase:. PHYSICIAN S Diagnosis Weight Allergies DETAILS Patient Care Patient Activity Bedrest Maintain Surgical Drain Maintain JP Drain, Measure Output q12h, and PRN Convert IV to INT when tolerating
Gemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
Pediatric Procedural Sedation
Pediatric Procedural Sedation Case 1: 2 year old complex facial laceration Judith R. Klein, MD, FACEP Assistant Professor of Emergency Medicine UCSF-SFGH Department of Emergency Medicine Objectives: The
PCA PRESCRIPTION is valid for a maximum of 4 days unless ceased earlier. Date: BINDING MARGIN - NO WRITING BINDING MARGIN - NO WRITING
Attach ADR Sticker THESE INSTRUCTIONS EXPLAIN WHEN TO MAKE A CLINICAL REVIEW OR RAPID RESPONSE CALL, YOUR LOCAL ESCALATION PROTOCOL WILL EXPLAIN HOW TO MAKE A CALL PCA ALLERGIES & ADVERSE DRUG REACTIONS
Satisfactory Analgesia Minimal Emesis in Day Surgeries. (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone
Satisfactory Analgesia Minimal Emesis in Day Surgeries (SAME-Day study) A Randomized Control Trial Comparing Morphine and Hydromorphone HARSHA SHANTHANNA ASSISTANT PROFESSOR ANESTHESIOLOGY MCMASTER UNIVERSITY
PHYSICIAN COMPETENCY FOR ADULT DEEP SEDATION (Ages 14 and older)
Name Score PHYSICIAN COMPETENCY FOR ADULT DEEP SEDATION (Ages 14 and older) 1. Pre-procedure evaluation for moderate sedation should involve all of the following EXCEPT: a) Airway Exam b) Anesthetic history
MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa
MARSHALLTOWN MEDICAL & SURGICAL CENTER Marshalltown, Iowa CARE OF PATIENT POLICY & PROCEDURES Policy Number: 4.44 Subject: Policy: Purpose: Moderate (Conscious) Sedation Conscious sedation will be ordered
ALL orders are active unless: 1. Order is manually lined through to inactivate 2. Orders with check boxes ( ) are unchecked DRUG AND TREATMENT ORDERS
DRUG AND TREATMENT Intubation Phase Notify Therapy for STAT intubation Medications SUB Rapid Sequence Induction (SUB)* ***Reminder: Order SUB Rapid Sequence Induction (SUB) on a separate form*** lidocaine
0.5 4 mcg/kg/hour. 4 mcg/kg/hour mg/kg/hour. 0.2 mg/kg/hour
PURPOSE* This guideline is intended to provide information about common critical care s in the pediatric emergency department. Information includes drug name, class, starting dose, titration information,
Sedation in children and young people. Appendix J. Sedation for diagnostic and therapeutic procedures in children and young people
SEDATION IN CHILDREN AND YOUNG PEOPLE 1 Sedation in children and young people Sedation for diagnostic and therapeutic procedures in children and young people Appendix J 2 SEDATION IN CHILDREN AND YOUNG
ADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
Note: Press F11 to maximize. Physician Education Procedural Sedation for ESJH
Note: Press F11 to maximize. Physician Education Procedural Sedation for ESJH 1 Definitions along the Sedation Continuum Responsiveness Airway Spontaneous Ventilation Cardiovascular Function Minimal Sedation
Pain: 1-2µg/kg q30-60min prn. effects in 10 minutes. Contraindications: Morphine is preferred in. Duration of Action: minutes. renal failure.
Procedural Sedation / Analgesia / Anaesthesia Chart - Page 1 Diazepam (Valium) Anxiolytic / Sedative Etomidate (Amidate) Hypnotic / Anesthetic Fentanyl Citrate (Sublimaze) Narcotic Analgesic Dose Pediatric:
PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain
Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name
Guideline for the Post Operative Management of Women who have received Intrathecal or Epidural Opioid Analgesia for Caesarean Section
Guideline for the Post Operative Management of Women who have received Intrathecal or Epidural Opioid Analgesia for Caesarean Section Speciality: Maternity Approval Body: Labour Ward Forum Approval Date:
Standard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
Guidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
SLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself.
SLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself. 1. Use the adult s nomogram to find the BSA of a person
Fairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45
Fairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45 1. Your diabetic patient is to be started on an insulin drip at 8 units/hour. The insulin is supplied: 100 units in
IV Sedation & Analgesia Update 2012
IV Sedation & Analgesia Update 2012 Hospital Directive No. 94 1 Read all content before taking test. Click on Right Arrow at top or bottom to advance to next page. 1 Hospital Directive No. 94 Purpose:
R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
Clinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation
High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma
High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton
Supportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study
Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes. ***See protocol for further details*** Available for Routine Use in
STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION
STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening
GUIDELINE FOR THE POST OPERATIVE MANAGEMENT OF WOMEN WHO HAVE RECEIVED INTRATHECAL OR EPIDURAL OPIOID ANALGESIA FOR CAESAREAN SECTION
GUIDELINE FOR THE POST OPERATIVE MANAGEMENT OF WOMEN WHO HAVE RECEIVED INTRATHECAL OR EPIDURAL OPIOID ANALGESIA FOR CAESAREAN SECTION Originator: Maternity Services & Anaesthetics Dept Date Approved: January
Paramedic Pediatric Medical Math Practice
Paramedic Pediatric Medical Math Practice Name: Date: Problem 1 Your 4 year old patient weighs 40 pounds. She is febrile. You need to administer acetaminophen (Tylenol) 15mg/kg. How many mg will you administer?
South Dakota State Board of Dentistry PO Box 1079, 1351 N. Harrison Ave. Pierre, SD Ph: Fax:
South Dakota State Board of Dentistry PO Box 1079, 1351 N. Harrison Ave. Pierre, SD 57501-1079 Ph: 605-224-1282 Fax: 888-425-3032 E-mail: contactus@sdboardofdentistry.com www.sdboardofdentistry.com PRACTITIONER
LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]
![LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]](/thumbs/84/89329197.jpg "LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]")
Page 1 of 7 PPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R] DAY DATE CHEMOTHERAPY 1 Start signature sheet and prednisolone
ASSESSMENT OF THE PAEDIATRIC NEEDS ANAESTHESIOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use ASSESSMENT OF THE PAEDIATRIC NEEDS ANAESTHESIOLOGY London, October 2006 Doc. Ref: EMEA/405166/2006 DISCLAIMER The Paediatric Working Party
Substitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
RECONSTITUTION, DOSING AND ADMINISTRATION
Prescribing Information can be found within this document CORRECT RECONSTITUTION FOR SC AND IV ADMINISTRATION VELCADE (bortezomib) 3.5 mg powder for solution for injection is available for intravenous
PAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
EPIDURAL / INTRATHECAL POST-OP PLAN
EPIDURAL / INTRATHECAL POST-OP PLAN Diagnosis Weight PHYSICIAN S Allergies Patient Care Vital Signs Per Unit Standards, PLUS check and record RR q1h x 12, then q2h x 6, until 24h following narcotic administration.
PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
Available ONLY at: BMC-B BMC-D BMC-N BMC-S Intubation Phase Notify Therapy for STAT intubation SUB Rapid Sequence Induction(SUB)* ***The above subphase is available at the end of the powerplan under the
PAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M
Rituximab + CODOX-M Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Burkitt
Sedation For Cardiac Procedures A Review of
Sedation For Cardiac Procedures A Review of Sedative Agents Dr Simon Chan Consultant Anaesthesiologist Department of Anaesthesia and Intensive Care Prince of Wales Hospital Hong Kong 21 February 2009 Aims
Ondansetron blocks the actions of chemicals in the body that can trigger nausea and vomiting.
1 of 6 6/10/2016 4:54 PM Generic Name: ondansetron (oral) (on DAN se tron) Brand Names: Zofran, Zofran ODT, Zuplenz What is ondansetron? Ondansetron blocks the actions of chemicals in the body that can
PEDIATRIC SPINE SURGERY POST-OP PLAN - Phase: Pediatric Spine Surgery General Orders
- Phase: Pediatric Spine Surgery General Orders PHYSICIAN S Diagnosis Weight Allergies Patient Care Patient Activity Bedrest Maintain Surgical Drain Maintain JP Drain, Measure Output q12h, and PRN Convert
SAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
CLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH
CLINICAL POLICY FOR THE USE OF INTRANASAL DIAMORPHINE FOR ANALGESIA IN CHILDREN ATTENDING THE PAEDIATRIC EMERGENCY DEPARTMENT, SASH Background Adequate analgesia is a vital aspect of early management of
Algorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
PROCEDURAL SEDATION AND ANALGESIA
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 Dr. Braam de Klerk VICTORIA BC 260 PROCEDURAL SEDATION AND ANALGESIA
Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30
If more information is required please seek help from specialist palliative care pioid dose conversion chart, syringe driver doses, rescue/prn doses and opioid patches Use the conversion chart to work
INTRAVENOUS LIDOCAINE INFUSIONS AND INTRALIPID RESCUE
INTRAVENOUS LIDOCAINE INFUSIONS AND INTRALIPID RESCUE Acute Pain Service-LHSC VH and UH sites HISTORY Lidocaine and procaine used by IV infusion in the 1950s and 1960s for general analgesia Often continued
** Medication exercises ** NICU Phase II
** Medication exercises ** NICU Phase II A) Baby A has had a bowel resection six hours ago. She weighs 3 kg. Post-op, she is quite agitated and she is on a fentanyl drip at 2 micrograms/kg/hr (#1). She
The Use of Midazolam to Modify Children s Behavior in the Dental Setting. by Fred S. Margolis, D.D.S.
The Use of Midazolam to Modify Children s Behavior in the Dental Setting by Fred S. Margolis, D.D.S. I. Introduction: One of the most common challenges that the dentist who treats children faces is the
Adult Drug Reference. Dopamine Drip Chart. Pediatric Drug Reference. Pediatric Drug Dosage Charts DRUG REFERENCES
Adult Drug Reference Dopamine Drip Chart Pediatric Drug Reference Pediatric Drug Dosage Charts DRUG REFERENCES ADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments ADENOSINE Paroxysmal
Medications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
Administration and Supply of Emergency Medicines
APPENDIX WHO CAN GIVE WHAT? Administration and Supply of Emergency Clinician Authorisation Key to Exemptions from legislation: NPP Non Parenteral POM. Can be given according to a protocol. 7 HMR 0, Schedule
ADENOSINE (Adenocard) VO = Intermediate Paramedic. ALBUTEROL SULFATE VO = EMT, EMT-IV, Intermediate Paramedic
ADENOSINE (Adenocard) ALBUTEROL SULFATE VO = EMT,, AMIODARONE (Cordarone) -except in cardiac arrest ASPIRIN EMT, ATROPINE SULFATE -except in cardiac arrest 1 ST dose 6 mg IVP, 2 ND dose 12 mg IVP, 3 rd
MICHIGAN. Table of Contents. State Protocols. General Treatment Protocols
MICHIGAN State Protocols General Treatment Protocols Table of Contents Protocol Number Protocol Name 1.1 General Pre-hospital Care: Regional Protocol 1.2 Abdominal Pain 1.3 Nausea and Vomiting: Regional
Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08)
Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08) Department of Pediatric Hematology/Oncology King Fahd National Centre for Children s Cancer and Research King Faisal Specialist Hospital and
WEIGHT: KG HEIGHT: CM ALLERGY CAUTION sheet reviewed Code Status Full code
(Page 1 of 5) Code Status Full code Status/Admit/Transfer/Discharge Surgical Procedure(s) and date performed: Cardiologist: Cardiac Surgeon: Intensivist: Patient Care CMV status Recipient CMV status Donor
R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)
R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case